Effect of leukocyte apheresis for refractory nephrotic syndrome

Effect of leukocyte apheresis for refractory nephrotic syndrome - Effect of leukocyte apheresis for refractory nephrotic syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010249

Enrollment

Registered

2013-04-01

Start date

2010-04-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

steroid-resistant nephrotic syndrome

Interventions

use of leukocyte apheresis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with steroid-resistant nephrotic syndrome 2) Patients without agreement

Exclusion criteria

Exclusion criteria: 1) Patients with severe heart failure 2) Patients with low blood pressure (systolic blood pressure less than 80mmHg) 3) Patients with white blood cell count of less than 3,000/mm3 4) Patients with anemia (hemoglobin less than 10g/dL) 5) Patients with thrombocytopenia (platelets less than 100,000/mm3) 6) Pregnant patient 7) Patients with drug abuse 8) Patients with cognitive disturbance 9) Patients with anaphylaxis for nafamostat mesilate 10) Patients having received inhibitor of angiotensin converting enzyme 11) Patients judged to be exclusive by investigators with another reason

Design outcomes

Primary

Measure	Time frame
improvement of proteinuria	—

Secondary

Measure	Time frame
renal function, white blood cell count, changes in histology of kidney	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026